Vortioxetine Improves Depressive Symptoms and Cognition in Parkinson’s Disease Patients with Major Depression: An Open-Label Prospective Study

Depression is frequent in Parkinson’s disease (PD) patients, but the evidence for many antidepressant agents to treat it in PD is insufficient. The aim of the present prospective open-label single-arm study (VOPARK, an open-label study of the effectiveness and safety of VOrtioxetine in PARKinson’s d...

Descripción completa

Detalles Bibliográficos
Autores principales: Santos García, Diego, Alonso Losada, Maria Gema, Cimas Hernando, Icíar, Cabo López, Iria, Yáñez Baña, Rosa, Alonso Redondo, Ruben, Paz González, Jose Manuel, Cores Bartolomé, Carlos, Feal Painceiras, Maria José, Íñiguez Alvarado, Maria Cristina, Labandeira, Carmen, García Díaz, Iago
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9688230/
https://www.ncbi.nlm.nih.gov/pubmed/36358393
http://dx.doi.org/10.3390/brainsci12111466

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9688230/
https://www.ncbi.nlm.nih.gov/pubmed/36358393
http://dx.doi.org/10.3390/brainsci12111466

Ejemplares similares